胃旁路术与袖状胃切除术后3年患者报告结局、体重减轻及2型糖尿病缓解:Oseberg单中心随机对照试验
Oseberg单中心随机试验纳入109例肥胖合并2型糖尿病患者,随机分配至胃旁路术(n=54)或袖状胃切除术(n=55),比较3年患者报告结局、体重减轻及糖尿病缓解。胃旁路术在体重相关生活质量、反流症状、总体重减轻及糖尿病缓解率上均优于袖状胃切除术,而腹痛、消化不良、腹泻、倾倒综合征、抑郁、暴食及食欲驱动等症状两组无差异。
要点
- 胃旁路术较袖状胃切除术显著改善体重相关生活质量(组间差值9.4,95%CI 3.3至15.5)。
- 胃旁路术反流症状更少(组间差值0.54,95%CI 0.17至-0.90)。
- 胃旁路术总体重减轻25% vs 袖状胃切除术17%(差值8%)。
核心结论
- 3年时,胃旁路术在体重相关生活质量、反流症状、体重减轻及糖尿病缓解方面优于袖状胃切除术。
- 腹痛、消化不良、腹泻、倾倒综合征、抑郁及暴食等症状两组无差异。
研究设计与样本
- Oseberg试验为单中心、平行组随机对照试验,在挪威滕斯贝格Vestfold Hospital Trust公立三级肥胖中心进行。
- 纳入109例年龄18岁及以上、既往证实BMI≥35.0 kg/m2的肥胖合并2型糖尿病患者,按1:1随机分配至胃旁路术(n=54)或袖状胃切除术(n=55)。
- 所有患者接受相同的术前和术后治疗,随机化采用计算机随机数生成器,区组大小为10。
- 研究 personnel、患者及主要结局评估者在1年内对分组设盲,分析采用意向性治疗人群。
主要发现
- 胃旁路术较袖状胃切除术在体重相关生活质量改善更明显(组间差值9.4,95%CI 3.3至15.5)。
- 胃旁路术反流症状更少(组间差值0.54,95%CI 0.17至-0.90)。
- 胃旁路术总体重减轻25% vs 袖状胃切除术17%(差值8%)。
- 胃旁路术糖尿病缓解率67% vs 袖状胃切除术33%(风险比2.00,95%CI 1.27至3.14)。
- 胃旁路术后第3年5例报告餐后低血糖 vs 袖状胃切除术后0例(p=0.059)。
关键数值与推荐
- 糖尿病诊断标准:糖化血红蛋白≥6.5%(48 mmol/mol)或使用抗糖尿病药物且糖化血红蛋白≥6.1%(43 mmol/mol)。
- 纳入标准:年龄18岁及以上,既往证实BMI≥35.0 kg/m2。
临床怎么用
- 作者认为,这些新的患者报告知识可用于共享决策过程,告知患者两种手术预期结局的相似与差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the comparative effects of various bariatric procedures on patient-reported outcomes. We aimed to compare 3-year effects of gastric bypass and sleeve gastrectomy on patient-reported outcome measures in patients with obesity and type 2 diabetes. METHODS: The Oseberg trial was a single-centre, parallel-group, randomised trial at Vestfold Hospital Trust, a public tertiary obesity centre in Tønsberg, Norway. Eligible patients were aged 18 years or older with previously verified BMI 35·0 kg/m2 or greater. Diabetes was diagnosed if glycated haemoglobin was at least 6·5% (48 mmol/mol) or by their use of anti-diabetic medications with glycated haemoglobin at least 6·1% (43 mmol/mol). Eligible patients were randomly assigned (1:1) to gastric bypass or sleeve gastrectomy. All patients received identical preoperative and postoperative treatment. Randomisation was done with a computerised random number generator and a block size of ten. Study personnel, patients, and the primary outcome assessor were blinded to allocations for 1 year. The prespecified secondary outcomes reported here were 3-year changes in several clinically important patient-reported outcomes, weight loss, and diabetes remission. Analyses were done in the intention to treat population. This trial is ongoing, closed to recruitment and is registered with ClinicalTrials.gov, NCT01778738. FINDINGS: Between Oct 15, 2012 and Sept 1, 2017, 319 consecutive patients with type 2 diabetes scheduled for bariatric surgery were assessed for eligibility. 101 patients were not eligible (29 did not have type 2 diabetes according to inclusion criteria and 72 other exclusion criteria) and 93 declined to participate. 109 patients were enrolled and randomly assigned to sleeve gastrectomy (n=55) or gastric bypass (n=54). 72 (66%) of 109 patients were female and 37 (34%) were male. 104 (95%) of patients were White. 16 patients were lost to follow up and 93 (85%) patients completed the 3-year follow-up. Three additional patients were contacted by phone for registration of comorbidities Compared with sleeve gastrectomy, gastric bypass was associated with a greater improvement in weight-related quality of life (between group difference 9·4, 95% CI 3·3 to 15·5), less reflux symptoms (0·54, 0·17 to -0·90), greater total bodyweight loss (8% difference, 25% vs 17%), and a higher probability of diabetes remission (67% vs 33%, risk ratio 2·00; 95% CI 1·27 to 3·14). Five patients reported postprandial hypoglycaemia in the third year after gastric bypass versus none after sleeve-gastrectomy (p=0·059). Symptoms of abdominal pain, indigestion, diarrhoea, dumping syndrome, depression, binge eating, and appetitive drive did not differ between groups. INTERPRETATION: At 3 years, gastric bypass was superior to sleeve gastrectomy in patients with type 2 diabetes and obesity regarding weight related quality of life, reflux symptoms, weight loss, and remission of diabetes, while symptoms of abdominal pain, indigestion, diarrhoea, dumping, depression and binge eating did not differ between groups. This new patient-reported knowledge can be used in the shared decision-making process to inform patients about similarities and differences between expected outcomes after the two surgical procedures. FUNDING: Morbid Obesity Centre, Vestfold Hospital Trust. TRANSLATION: For the Norwegian translation of the abstract see Supplementary Materials section.
引用
- Svanevik M, Lorentzen J, Borgeraas H, et al. Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial. Lancet Diabetes Endocrinol. 2023. PMID: 37414071. doi:10.1016/S2213-8587(23)00127-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。